Project Grant R01AI198272
Award Date 8/4/26
Completion Date 7/31/31
Dollars Obligated $810K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60637, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The University of Chicago $1,229,998 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel TH17-inducing mucosal tuberculosis vaccine. The research advances preclinical development of NETB-EA, a nanoemulsion-based vaccine candidate that delivers immunodominant Mycobacterium tuberculosis antigens (AG85B and ESAT6) via intranasal vaccination to induce T helper type 17 cell...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded $736,079 to the University of Chicago on July 8, 2026, for research investigating the role of commensal-reactive gamma delta T cells in anti-tuberculosis immunity under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project, titled "Role of Commensal-Reactive Gamma Delta T Cells in Anti-Tuberculosis Immunity," examines how specific...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services National Institutes of Health, awarded Beth Israel Deaconess Medical Center, Inc. $1,296,750 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel trivalent adjuvanted tuberculosis vaccine. The research will characterize and advance a trivalent TB vaccine candidate consisting of three antigens—PPE20 (RV1387), ESXG (RV0287), and...
- The National Institute of Allergy and Infectious Diseases awarded The University of Chicago $1,177,657 on July 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the biophysical and structural basis of T cell selection at the intersection of conventional and regulatory T cell repertoires. The research addresses autoimmune disease pathogenesis by examining how CD4+ T cells recognize peptide antigens complexed with MHC class II molecules through the T...
- The National Institute of Allergy and Infectious Diseases awarded the University of Massachusetts Medical School $460,625 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immune mechanisms underlying BCG vaccine protection against tuberculosis. The research uses Collaborative Cross mouse strains to identify immune signatures associated with vaccine-induced TB protection across genetically diverse host populations. The study focuses on a...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin - Madison $717,003 on April 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and assess protective mRNA vaccines against tuberculosis. The project focuses on evaluating the safety, immunogenicity, and protective efficacy of QRNA, a novel mRNA vaccine delivered via QUILA-DOTAP (QTAP), a lipid nanoparticle adjuvant designed for stable mRNA delivery across...
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $315,700 on January 29, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research elucidating spatio-temporal innate immune cell modulation of Mycobacterium tuberculosis stress response and replication heterogeneity. The project investigates how spatial organization of tuberculosis lesions in the lung...
- The National Institute of Allergy and Infectious Diseases awarded $1.59 million to the University of Colorado-Denver under Project Grant R01AI187511 on September 17, 2025, to support research integrating genomic architecture and tuberculosis immunity in Africa under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research generates population-level genetic data (HLA, KIR, and SNP array) on 5,000 case/control samples from multi-ancestry individuals in South Africa's...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $427,623 to The Washington University on February 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research dissecting how HIV-induced immunometabolic perturbation impairs tuberculosis control in people living with HIV despite effective antiretroviral therapy and viral suppression. The research...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $3,068,770 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop neuraminidase-based influenza vaccines with broad protective immunity. The research systematically analyzes the structure-function relationships of neuraminidase monoclonal antibodies, maps the affinity maturation pathways leading to broadly protective antibodies, and engineers a broadly...